Technical Analysis for BMY - Bristol-Myers Squibb Company

Grade Last Price % Change Price Change
F 50.31 0.30% 0.15
BMY closed up 0.3 percent on Friday, December 8, 2023, on 81 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Shooting Star Candlestick Bearish 0.30%
Crossed Above 20 DMA Bullish 0.30%
Gapped Up Strength 0.30%
Fell Below 20 DMA Bearish 0.86%
Multiple of Ten Bearish Other 0.86%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 2 days ago
Possible Inside Day 2 days ago
Up 1 ATR 3 days ago
Up 2% 3 days ago
60 Minute Opening Range Breakout 3 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Bristol-Myers Squibb Company Description

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company's products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Biopharmaceutical Diabetes Cancer Treatment Clinic Pharmaceutical Products Hypertension Melanoma Schizophrenia Rheumatoid Arthritis Hepatitis B Multiple Myeloma Stroke Dystrophy Epidermal Growth Factor Receptor Depressive Disorder Hepatitis C Immunodeficiency Hepatitis C Virus Organic Chemistry Diabetic Nephropathy Hepatitis B Virus Atrial Fibrillation Interferon Biopharmaceutical Products Treatment Of Diabetes Chronic Myeloid Leukemia Heart Attack Hepatitis C Virus Infection Metastatic Melanoma Transplant Rejection Treatment Of Hypertension Kidney Transplant Leptin Lipodystrophy

Is BMY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 76.6288
52 Week Low 48.252
Average Volume 12,478,196
200-Day Moving Average 61.01
50-Day Moving Average 52.88
20-Day Moving Average 49.89
10-Day Moving Average 49.67
Average True Range 0.99
RSI (14) 45.95
ADX 35.55
+DI 20.03
-DI 25.18
Chandelier Exit (Long, 3 ATRs) 49.61
Chandelier Exit (Short, 3 ATRs) 51.22
Upper Bollinger Bands 51.47
Lower Bollinger Band 48.30
Percent B (%b) 0.63
BandWidth 6.35
MACD Line -0.78
MACD Signal Line -1.11
MACD Histogram 0.3229
Fundamentals Value
Market Cap 113.69 Billion
Num Shares 2.26 Billion
EPS 0.51
Price-to-Earnings (P/E) Ratio 98.07
Price-to-Sales 3.46
Price-to-Book 2.78
PEG Ratio 0.82
Dividend 1.80
Dividend Yield 3.58%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 50.98
Resistance 3 (R3) 50.98 50.76 50.87
Resistance 2 (R2) 50.76 50.59 50.76 50.83
Resistance 1 (R1) 50.53 50.48 50.65 50.53 50.79
Pivot Point 50.31 50.31 50.37 50.31 50.31
Support 1 (S1) 50.09 50.14 50.20 50.09 49.83
Support 2 (S2) 49.87 50.04 49.87 49.79
Support 3 (S3) 49.64 49.87 49.75
Support 4 (S4) 49.64